Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis

Authors: Wen Zheng, Ya Zhou, Jia Lu, Hualin Xu, Liangyu Lei, Chao Chen, Juanjuan Zhao, Lin Xu

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Objective

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death. Growing evidence from recent studies have shown indicated that microRNA-126 (miR-126) played an important role in the progression of NSCLC. However, the potential value of miR-126 expression in prognosis of NSCLC remains to be fully elucidated. Here, we carried out a meta-analysis to assess the potential prognostic value of miR-126 for NSCLC.

Methods

PubMed, Embase, the Cochrane library, Web of Science, CNKI and WanFang database, as well as the reference of included studies, were searched to recognize pertinent studies until April 30, 2017. New castle-Ottawa scale was used to evaluate the quality of studies. Pooled hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS) was extracted by using a fixed-effects or a random-effects model on the basis of heterogeneity. Publication bias was evaluated by using Begg’s tests.

Results

We identified four eligible trials involving 666 non-small-cell lung cancer patients in this meta-analysis. The results indicated that a high level of miR-126 played a favorable role in the overall survival (HR 0.73, 95% CI 0.61–0.86, fixed-effects model). There was no bias existed in this study.

Conclusions

Our study showed that high expression level of miR-126 was a promising positive factor for OS for non-small cell lung cancer patients, and miR-126 might be a potential target for non-small-cell lung cancer therapy in the future.
Literature
1.
2.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
3.
4.
Watanabe T, Miura T, Degawa Y, et al. Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR. Cancer Cell Int. 2010;10:2.CrossRefPubMedPubMedCentral
5.
6.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.CrossRefPubMed
7.
Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12(12):580–7.CrossRefPubMed
8.
9.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.CrossRefPubMed
10.
11.
Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. Sci World J. 2010;10:2090–100.CrossRef
12.
Qin A, Wen Z, Zhou Y, et al. MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med. 2013;17(2):252–64.CrossRefPubMedPubMedCentral
13.
Tafsiri E, Darbouy M, Shadmehr MB, et al. Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells. J Cancer Res Ther. 2016;12(1):395–400.CrossRefPubMed
14.
Tafsiri E, Darbouy M, Shadmehr MB, et al. Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumor Biol. 2015;36(3):1603–12.CrossRef
15.
Hu X, Zhang F, Liu XR, et al. Efficacy and potential microRNA mechanism for computed tomography-guided percutaneous radiofrequency ablation of primary lung cancer and lung metastasis from liver cancer. Cell Physiol Biochem. 2014;33(5):1261–71.CrossRefPubMed
16.
Tsay JJ, Tchou-Wong K, Yie T, et al. Bronchial brushings’ microRNA and field cancerization in lung adenocarcinoma. Am J Respir Criti Care Med. 2013;187:A4753.
17.
Markou A, Sourvinou I, Vorkas PA, et al. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013;81(3):388–96.CrossRefPubMed
18.
Wang Y, Shi J, Wu Y, et al. Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application. Tumori. 2012;98(6):792–9.PubMed
19.
Guan P, Yin Z, Li X, et al. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012;31(1):54.CrossRefPubMedPubMedCentral
20.
Kausar H, Jeyabalan J, Aqil F, et al. Berry anthocyanidins synergistically suppresses non-small-cell lung cancer cell growth and metastasis and enhances sensitivity to the chemotherapeutic drug paclitaxel. J Thorac Oncol. 2011;6(6):S930–1.
21.
Guo M, Huang M, Calin GA, et al. Altered microRNA expression in adenocarcinoma of lung from smokers and never-smokers. Lab Invest. 2011;91:443A.
22.
Yang Y, Li X, Yang Q, et al. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet. 2010;200(2):127–33.CrossRefPubMed
23.
Sun Y, Bai Y, Zhang F, et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 2010;391(3):1483–9.CrossRefPubMed
24.
Song L, Li D, Gu Y, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer. 2016;5:e65–75.CrossRef
25.
Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008;373(4):607–12.CrossRefPubMed
26.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
27.
Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE. 2013;8(1):e54596.CrossRefPubMedPubMedCentral
28.
Donnem T, Lonvik K, Eklo K, et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer. 2011;117(14):3193–200.CrossRefPubMed
29.
Jusufovic E, Rijavec M, Keser D, et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS ONE. 2012;7(9):e45577.CrossRefPubMedPubMedCentral
30.
Chen S-W, Wang T-B, Tian Y-H, et al. Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):14983–8.PubMedPubMedCentral
31.
Kim MK, Jung SB, Kim J-S, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch. 2014;465(4):463–71.CrossRefPubMed
32.
Li X, Wan YL, Sun C, et al. Effect of miR-126 on cell cycle regulation and prognosis of lung cancer patients. J Pract Oncol. 2014;29(5):440–5.
33.
Yang J, Lan H, Huang X, et al. MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. Plos ONE. 2012;7(8):e42978.CrossRefPubMedPubMedCentral
34.
Song L, Li D, Gu Y, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer. 2016;17(5):e65–75.CrossRefPubMed
35.
Zhong M, Ma X, Sun C, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem Biol Interact. 2010;184(3):431–8.CrossRefPubMed
36.
Wang XC, Du LQ, Tian LL, et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer. 2011;72(1):92–9.CrossRefPubMed
37.
Zhu X, Li H, Long L, et al. MiR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin. 2012;44(6):519–26.CrossRefPubMed
38.
An Q, Han C, Zhou Y, et al. Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep. 2016;14(5):4042–8.PubMedPubMedCentral
39.
Jin X, Xie C. Evaluation of exosomal miRNAs from plasma as potential biomarker for NSCLC. J Thorac Oncol. 2017;12(1):S350–1.CrossRef
40.
Chen Q, Hu H, Jiao D, et al. MiR-126-3p and miR-451a correlate with clinicopathological features of lung adenocarcinoma: the underlying molecular mechanisms. Oncol Rep. 2016;36(2):909–17.PubMed
41.
Shang AQ, Xie YN, Wang J, et al. Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study. Neoplasma. 2017;64(3):453–9.CrossRefPubMed
42.
Lin Q, Mao W, Shu Y, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol. 2012;138(1):85–93.CrossRefPubMed
43.
Yan J, Ma S, Zhang Y, et al. Potential role of microRNA-126 in the diagnosis of cancers: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(35):e4644.CrossRef
44.
Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91(4):579–87.CrossRefPubMed
45.
Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE. 2016;11(4):e0153046.CrossRefPubMedPubMedCentral
46.
Ilie M, Sanfiorenzo C, Brest P, et al. Plasma miR-155, miR-152, miR-20a, miR-223, miR-126 and miR-199a expression as a novel prognostic signature of resectable non-small cell lung carcinoma (NSCLC). Virchows Arch. 2012;461(1):S51–2.
47.
Song R, Liu Q, Hutvagner G, et al. Rule discovery and distance separation to detect reliable miRNA biomarkers for the diagnosis of lung squamous cell carcinoma. BMC Genom. 2014;15(9):S16.CrossRef
48.
Kim MH, Jo EJ, Eom JS, et al. Diagnostic value of microRNAs derived exosomes from bronchoalveolar lavage fluid in early stage lung adenocarcinoma. Chest. 2016;150(4):703A.CrossRef
49.
Ilie M, Sanfiorenzo C, Brest P, et al. Plasma miR-155, miR-152, miR-20a, miR-223, miR-126 and miR-199a expression as a novel prognostic signature of resectable non-small cell lung carcinoma (NSCLC). Virchows Arch. 2012;461:S51–2.
50.
Markou A, Sourvinou I, Vorkas PA, et al. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 2013;81(3):388–96.CrossRefPubMed
51.
Lønvik K, Wsørbye S, Nilsen MN, et al. Prognostic value of the microRNA regulators Dicer and Drosha in non-small-cell lung cancer:co-expression of Drosha and miR-126 predicts poor survival. BMC Clin Pathol. 2014;14(1):45.CrossRefPubMedPubMedCentral
Metadata
Title
The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis
Authors
Wen Zheng
Ya Zhou
Jia Lu
Hualin Xu
Liangyu Lei
Chao Chen
Juanjuan Zhao
Lin Xu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0440-8

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene

Primary research

MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7

Primary research

Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand

Primary Research

Alginate-embedded HuH-7 cells increase MMP-9 and reduce OCLN expression in vitro

Primary Research

The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells

Retraction Note

Retraction Note to: Mutation pattern is an influential factor on functional mutation rates in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits